TickerTalks
Browse all tickers →
TickerTalks›$NVO
NVNVO

Novo Nordisk A/S

$NVO·$210B·Drug Manufacturers - General·Healthcare
$45.33-0.6%YTD-14.2%1Y-19.6%
Mentions · last 7 days
2026-08-22: 31 posts2026-08-23: 43 posts509-2%
Price updated 6h ago·X counts updated 8d ago
NVNVO
$NVONovo Nordisk A/S
$45.33-0.61%509 posts-2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NVO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptStalledAI verdict · as of 2026-08-30

The move has stalled — likely just drifts unless something new shows up.

The GLP-1 leader trading at 10x earnings after a brutal derating — Oral Wegovy dominating in the US but nobody in management is buying.

Novo Nordisk is the diabetes/obesity giant that led the GLP-1 wave and has since been de-rated on the reality that Lilly is competing hard and the shortage that supported compounded copies is over. It now trades at pharma-cyclical multiples on a franchise that's still growing.

How the setup actually reads:

  • Oral Wegovy is quietly dominating: ~143K weekly US scripts is roughly 9x Lilly's Foundayo, and NVO just filed Oral Wegovy for China — an oral GLP-1 at scale is the catalyst the bear case doesn't credit.
  • The shortage-end call is a net positive: FDA affirmed the GLP-1 shortage is over, which kills compounded copies and pulls grey-market volume back to branded — visible in coming quarters, not this print.
  • Valuation is low for the profile: 10.3x earnings, 3.8x sales, 7.5x EV/EBITDA on a business earning 45% operating margins and 32% ROIC — cheapest the mega-pharma cohort trades for these fundamentals, and the buyback (29.9M shares since February) is running through it.
  • Signals against are real: Deutsche Bank downgrade to Sell (growth concerns), zero insider buying in 2026 at a decade-low multiple, and sector fatigue with weight-loss headlines — why the multiple hasn't compressed further, but hasn't rerated either.

The November 4 print breaks the stall — a US script re-acceleration into the shortage-end effect plus Oral Wegovy China progress starts the rerate; another flat quarter with no insider buys, and the multiple stays compressed through year-end.

What to watch: November 4 earnings — Oral Wegovy US script trend post-shortage-end and any progress on the China filing; a US script re-acceleration starts the rerate, another flat quarter with no insider buys keeps the multiple compressed through year-end.

On the calendar: 2026-11-04 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment149 posts analyzed · as of 2026-08-31

Discussion is mixed on Novo Nordisk, with camps openly disagreeing. Bulls anchor on a "textbook accumulation" thesis at 13-15x forward P/E, JPMorgan's raise to DKK 275, an FDA appeals-court win against compounders, and Oral Wegovy dominating Lilly's Foundayo (~175K vs ~40K weekly scripts). Bears cite Deutsche Bank's Sell downgrade, PepsiCo dropping GLP-1 coverage, absent insider buying, and calls of a "value trap" as Lilly extends its lead.

Read the AI verdict + X sentiment for $NVO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes GLP-1 drugs Ozempic and Wegovy for diabetes and obesity with semaglutide driving blockbuster revenue growth.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $NVO.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $NVO

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+45.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
10.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
66.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
81.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.96$0.82+17.1%
Q1 2026May 6, 2026$1.04$0.87+19.5%
Q4 2025Feb 3, 2026$1.00$0.90+11.1%
Q3 2025Nov 5, 2025$1.02$0.77+32.5%
Next earningsWed, Nov 4·consensus EPS $0.80

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$96.8B+24.0%86.0%61.6%$10.93$12.0B
Q4 FY25$79.1B-7.6%80.9%40.1%$6.06$-36.2B
Q3 FY25$75.0B+5.1%76.1%31.6%$4.50$30.7B
Q2 FY25$76.9B+12.9%83.3%43.5%$5.96$24.5B

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$290.6B$278.7B – $302.9B$21.42$19.40 – $23.6316
FY27$298.2B$284.4B – $313.8B$21.44$20.20 – $24.2616
FY28$317.6B$294.3B – $350.5B$23.18$20.96 – $26.2914
FY29$346.2B$320.8B – $382.0B$26.47$23.94 – $30.0315
FY30$363.4B$336.7B – $401.0B$27.78$25.13 – $31.5115

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.35%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-2.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 3.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.355-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 42 other (37 6-Ks · 2 13Gs · 2 11-Ks · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

GLP-1 weight loss drugs effective even at low starter dosesreuters.com·8h agoTrump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakerscnbc.com·13h agoCan CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?zacks.com·15h agoHas Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?fool.com·2d agoNovo Nordisk stock falls as Deutsche Bank downgrades shares to sellinvezz.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$JNJ$GILD$ABBV$AMGN$AZN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport